Disclosures for "Utility of 18F-FDG PET/CT in Follow-up of Patients with Neurofibromatosis Type 1: A Clinical Registry Study of 79 Adult Patients"
-
Miss Tanase has nothing to disclose.
-
Miss Djilani has nothing to disclose.
-
Mrs. Leclerc has nothing to disclose.
-
Mrs. Baril has nothing to disclose.
-
Author has nothing to disclose
-
Mathieu Blais has nothing to disclose.
-
Prof. Gros-Louis has nothing to disclose.
-
Dr. Dupre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Akcea Therapeutics Canada. The institution of Dr. Dupre has received research support from ARSACS Foundation. The institution of Dr. Dupre has received research support from CHUdeQuebec Foundation.